Cyclosporine Market Size To Hit USD 9.44 Billion By 2032, Driven By Rising Organ Transplants And Expanding Therapeutic Applications S&S Insider

(MENAFN- GlobeNewsWire - Nasdaq) As per S&S Insider Research, Growing prevalence of organ failure, expanding access to transplantation, and rising demand for dry eye therapies position the cyclosporine market for strong double-digit growth through 2032.

Austin, Sept. 23, 2025 (GLOBE NEWSWIRE) -- According to S&S Insider, the global cyclosporine market was valued at USD 3.15 billion in 2024 and is projected to reach USD 9.44 billion by 2032, growing at a CAGR of 14.76% during 2025–2032. Cyclosporine continues to play a central role in transplant medicine as a cornerstone immunosuppressant, safeguarding long-term graft survival and minimizing rejection risks.

The U.S. market alone was worth USD 1.00 billion in 2024 and is forecast to reach USD 2.98 billion by 2032 at a CAGR of 14.67%. Stringent FDA regulatory oversight, widespread provider trust in branded formulations, and high transplant volumes contribute to the U.S. maintaining its leadership position.

Get Sample Report of Cyclosporine Market @

Market Drivers

• Rising number of organ transplants worldwide, supported by greater donor availability and healthcare infrastructure improvements.
• Established role of cyclosporine in preventing rejection, ensuring graft survival, and improving post-transplant outcomes.
• Increasing demand for chronic immunosuppressive therapy in both hospital and homecare settings.

Major Players Analysis Listed in the Cyclosporine Market Report are

• Novartis AG
• AbbVie Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Mylan
• Apotex Inc.
• Zydus Lifesciences Ltd.
• Amneal Pharmaceuticals, Inc.
• Intas Pharmaceuticals Ltd.
• Sandoz

Cyclosporine Market Report Scope

Report Attributes	Details
Market Size in 2024	USD3.15 billion
Market Size by 2032	USD 9.44 billion
CAGR	CAGR of 14.76% From 2025 to 2032
Base Year	2024
Forecast Period	2025-2032
Historical Data	2021-2023
Regional Analysis	North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)

Segmentation Analysis:

By Indication

Rejection of Transplants Since prophylaxis is crucial for preventing organ rejection following kidney, liver, and heart transplants, it holds a 45.94% market share in 2024, making it the leading category of the global cyclosporine market. Due to increased awareness of OSDs, aging populations, and extended screen time, the dry eye segment of the global cyclosporine market is expanding at the quickest rate, with a compound annual growth rate (CAGR) of 16.10%.

By Route of Administration

As oral medications are the most often prescribed treatment for persistent immunosuppression in transplant and autoimmune patients, they held a 58.80% market share in 2024, dominating the cyclosporine sector. According to the cyclosporine market data, the topical sector is expanding at the fastest rate due to an increase in the prevalence of dry eye disease and regional inflammatory skin illnesses.

By End-Users

Driven by the largest acute care and transplantation processing centers, Hospitals Care held a leading market share of 52.40% of the cyclosporine industry in 2024. With the highest CAGR of 15.54%, the homecare area of the cyclosporine market is on the rise, driven by the increasing need for simple and long-lasting treatments for chronic conditions such autoimmune disorders and dry eye.

By Distribution Channel

Hospital pharmacies are the initial point of distribution for transplant-related medications, including cyclosporine and other life-saving immunosuppressants, making them the largest portion of the cyclosporine industry. The Online Pharmacy segment is witnessing the highest growth in the cyclosporine market, fuelled by growing digital health adoption, the attractiveness of home delivery, and the broadening of e-commerce access to prescription medicine.

Need Any Customization Research on Cyclosporine Market, Enquire Now:

Cyclosporine Market Key Segments

By Indication

• Transplant Rejection Prophylaxis
• Rheumatoid Arthritis
• Psoriasis
• Autoimmune Myasthenia Gravis
• Dry Eye
• Others

By Route of Administration

• Oral
• Injectable
• Topical

By End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Regional Analysis

North America leads the global cyclosporine market, holding 38.60% of total share in 2024. The region's dominance stems from advanced healthcare infrastructure, high transplant volumes, robust insurance coverage, and FDA's stringent safety requirements. Strong trust in branded drugs and active clinical trials further strengthen regional leadership.

Asia Pacific is the fastest-growing region with a projected CAGR of 15.42%. Rapid improvements in healthcare access, rising transplant infrastructure in countries like China and India, and increased awareness of autoimmune and ophthalmic disorders drive demand. Availability of cost-effective generic formulations further accelerates growth.

Recent News:

• In March 2024, Novartis announced continued investment in Neoral lifecycle management, with new post-marketing studies in Europe focusing on improving dosing strategies in liver transplant patients.
• In February 2024, Viatris scaled production of generic cyclosporine modified capsules at its manufacturing unit in Hungary to meet rising EU transplant demand.

Buy the Cyclosporine Market Report Now:

Exclusive Sections of the Report (The USPs) – Check Section 5

• INCIDENCE & PREVALENCE METRICS – helps you understand disease burden and patient population size, forming the basis for demand forecasting and market potential analysis.
• PRESCRIPTION TRENDS BY REGION – helps you track regional prescribing behavior, physician adoption, and therapy preference patterns in key geographies.
• DRUG VOLUME – PRODUCTION & USAGE – helps you analyze historical and projected production-output trends and consumption rates of cyclosporine from 2020 to 2032.
• HEALTHCARE SPENDING BENCHMARKS – helps you evaluate pharmaceutical budget allocations, cost pressures, and the impact of spending dynamics on cyclosporine adoption.
• REGULATORY COMPLIANCE & MARKET ACCESS – helps you assess approval pathways, compliance requirements, and market entry barriers across different healthcare systems.

Access Complete Report Details of Cyclosporine Market Analysis & Outlook@

About Us:

S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: ...

MENAFN23092025004107003653ID1110099172